# Dose Range-finding Study of ASP1585 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia

> **NCT02753894** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 73 (actual)

## Conditions studied

- Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia

## Interventions

- **DRUG:** ASP1585

## Key facts

- **NCT ID:** NCT02753894
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2016-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02753894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02753894, "Dose Range-finding Study of ASP1585 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02753894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*